PPARGC1A and type 2 diabetes mellitus: Prevention of Ppargc1a overexpression in islets of type 2 diabetes models or in response to glucolipotoxity improve islet function, yet its total knock out in islet beta-cells causes impaired islet function (46, 47) suggesting complex important roles for this co-activator in islet beta-cells.